STAT3 pathway inhibitor and cancer stem cell pathway inhibitors that one class is new

STAT3 pathway inhibitor and cancer stem cell pathway inhibitors that one class is new

  • CN 101,854,930 B
  • Filed: 09/10/2008
  • Issued: 05/04/2016
  • Est. Priority Date: 09/10/2007
  • Status: Active Grant
First Claim
Patent Images

1. Stat3 pathway inhibitor shifts to treat in the Stat3 pathway activity for the preparation of in inhibition cancer stem cellProperty, the cancer obstinate, inherent resistance chemotherapy or recurrent of chemotherapy or radiotherapy, and anti-cancer in advancePurposes in the transfer of disease or recurrence medicine, wherein Stat3 pathway inhibitor is selected from the chloro-naphtho-of 2-acetyl group-7-[2,3-b] furans-4,9-diketone, the fluoro-naphtho-of 2-acetyl group-7-[2,3-b] furans-4,9-diketone, 2 acetyl naphthalene are also[2,3-b] furans-4,9-diketone, 2-ethyl-naphtho-[2,3-b] furans-4,9-diketone, mono phosphoric acid ester-[1-(4,9-dioxo-3a, 4,9,9a-tetrahydrochysene-naphtho-[2,3-b] furans-2-yl)-vinyl] ester or phosphatase 11-(4,9-dioxo-3a, 4,9,9a-Tetrahydrochysene-naphtho-[2,3-b] furans-2-yl)-vinyl esters dimethyl ester and officinal salt thereof, wherein said cancer isKnow the cancer that there is cancer stem cell and have simultaneously abnormal Stat3 pathway activity.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×